Skip to content

Evaluation of the administration of CoQ10 tablets in poisoning with aluminum phosphide tablets

Evaluation of the administration of CoQ10 tablets with standard protocol in poisoning with aluminum phosphide tablets

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20130917014693N14
Enrollment
50
Registered
2022-05-14
Start date
2022-05-21
Completion date
Unknown
Last updated
2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Poisoning with aluminum phosphide tablets. Toxic effect of pesticides

Interventions

Intervention 1: Intervention group: In addition to receiving the national protocol for the treatment of aluminium phosphide poisoning (including vitamin E, NAC, magnesium sulfate, calcium gluconate an

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: People over 18 years old People diagnosed with aluminum phosphide poisoning within 24 hours of being diagnosed with poisoning. Signing the informed consent form by the patient or his / her legal guardian

Exclusion criteria

Exclusion criteria: Heart failure Acute renal failure Chronic liver failure Chronic renal failure History of acute myocardial infarction Patients with a history of allergy to administered medicines

Design outcomes

Primary

MeasureTime frame
Death rate. Timepoint: Duraing the study. Method of measurement: Using the patient's clinical record.

Secondary

MeasureTime frame
Changes in the results of arterial blood gas analysis. Timepoint: On a daily basis from the beginning of the drug administration to the end of the study. Method of measurement: The GEM Premier 3000 device is used to measure arterial blood gases.;Duration of hospitalization. Timepoint: On a daily basis from the beginning of the drug administration to the end of the study. Method of measurement: Using the patient's clinical record.;Blood pressure. Timepoint: On a daily basis from the beginning of the drug administration to the end of the study. Method of measurement: Sphygmomanometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Zahra Sahraei

Shahid Beheshti University of Medical Sciences

z.sahraei@sbmu.ac.ir+98 21 8820 0118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026